Inhalation Sciences: key patent approved in Europe
(Stockholm, 30 June 2020) Inhalation Sciences (ISAB) has received European approval, with no restrictions, for a key patent that covers the company’s unique simplified method to accomplish so called “regional targeting”— or being able to selectively direct aerosol exposures to the different main regions in the lung.
Regional targeting gives new opportunities to map how either drug substances or air pollutants work in the lungs. The patent with reference number EP2173419 has previously been approved in the US and China, but is now also approved on the important European market without restrictions.
CEO Manoush Masarrat: “Being able to target aerosols to the major regions of the respiratory tract has previously been a technical challenge. However, with the new method from Inhalation Sciences this procedure has become much easier. Regional targeting gives pharma developers and toxicologists a significant competitive advantage, delivering leading data of exceptional detail and precision.”
For more information about Inhalation Sciences, please contact:
Manoush Masarrat, CEO
E-mail: Manoush.masarrat@inhalation.se
Mobile: +46 (0)73 628 9153
About Inhalations Sciences Sweden AB (publ)
Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments for research into inhalation. The company’s patented lab instrument, PreciseInhale®, enables researchers to characterize, with high precision, how aerosols and small particles impact our lungs, and so our health, when we inhale them.
Tags: